Treatment Patterns and Annual Drug Costs of Biologic Therapies Across Indications from the Humana Commercial Database

Abstract

The tumor necrosis factor blockers adalimumab, etanercept, and infliximab were the most commonly used biologics across indications. New patients were less persistent than those continuing on therapy. Among new patients, adalimumab had the lowest mean annual cost per treated patient, and etanercept had the lowest mean annual cost per treated patient among those continuing on therapy.